ALK-Abelló


	Home Contact Site index


Search

Products for diagnosis, prevention and treatment of allergies

Welcome to
the ALK-Abelló
corporate website

Other ALK-Abelló sites

Visit the investor site of ALK-Abelló

Positive third year results with GRAZAX®

ALK-Abelló announces highly significant and positive third year results from clinical study with GRAZAX® which support expectations of a long-term disease-modifying effect of the therapy....>> more

2007 Annual Report
English
Danish

Congress activities 2008
Calendar & scientific contributions

Specific Allergy Symposium (SOSA)
Copenhagen, 24-26 April 08

Report on the Annual General Meeting of ALK-Abelló A/S held on April 24, 2008
The AGM of ALK-Abelló A/S held on April 24, 2008 transacted the following business

ALK-Abelló, the makers of GRAZAX®, Present Successful Phase III Clinical Study Results with Children
Results show highly significant effect on rhinoconjunctivitis (hay fever) and asthma symptoms in children from age 5 to 16 years-old

ALK-Abelló A/S announces annual report for 2007
The Board of Directors of ALK-Abelló A/S has today approved the annual report for the period January 1 - December 31, 2007


	ALK-Abelló A/S \| 6-8 Bøge Allé \| DK-2970 Hørsholm \| CVR no. 63 71 79 16 \| Tel. +45 4574 7576


Legal disclaimer Print page